AccessPak for HIV PEP Expanded with Kaletra Interactions
There are 920 drugs known to interact with AccessPak for HIV PEP Expanded with Kaletra (emtricitabine/lopinavir/ritonavir/tenofovir disoproxil), along with 12 disease interactions, and 5 alcohol/food interactions. Of the total drug interactions, 405 are major, 485 are moderate, and 30 are minor.
- View all 920 medications that may interact with AccessPak for HIV PEP Expanded with Kaletra
- View AccessPak for HIV PEP Expanded with Kaletra alcohol/food interactions (5)
- View AccessPak for HIV PEP Expanded with Kaletra disease interactions (12)
Most frequently checked interactions
View interaction reports for AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil) and the medicines listed below.
- alendronate
- amlodipine
- armodafinil
- Ativan (lorazepam)
- Augmentin (amoxicillin / clavulanate)
- Bactrim (sulfamethoxazole / trimethoprim)
- Basaglar (insulin glargine)
- BeneFix (coagulation factor ix)
- betamethasone topical
- Bexxar (iodine i 131 tositumomab)
- celecoxib
- CellCept (mycophenolate mofetil)
- ciprofloxacin
- clindamycin topical
- clobetasol topical
- Coreg (carvedilol)
- cranberry
- dicyclomine
- Dificid (fidaxomicin)
- Doans Pills Extra Strength (magnesium salicylate)
- docosanol topical
- Dulcolax (bisacodyl)
- Easprin (aspirin)
- Eldepryl (selegiline)
- Enbrel (etanercept)
- EpiPen (epinephrine)
- ezetimibe
- famotidine
- Fast Sleep (doxylamine)
- Klonopin (clonazepam)
AccessPak for HIV PEP Expanded with Kaletra alcohol/food interactions
There are 5 alcohol/food interactions with AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil).
AccessPak for HIV PEP Expanded with Kaletra disease interactions
There are 12 disease interactions with AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil) which include:
- hepatitis B
- hepatotoxicity
- hemodialysis
- renal dysfunction
- hemophilia
- hyperglycemia
- hyperlipidemia
- heart block
- hepatotoxicity
- bone toxicity
- liver disease
- renal dysfunction
Report options
More about AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil)
- AccessPak for HIV PEP Expanded with Kaletra consumer information
- Compare alternatives
- Side effects
- Drug class: antiviral combinations
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.